Stock Ratings / Industrials / IDXG / financials

JBDI (45) BHST (34) RML (58) STKE (50) ⌘ Pro Terminal →

Interpace Biosciences Inc. (IDXG) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$5.72 +15.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.87

Interpace Biosciences Inc. (IDXG) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $23.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.87 (+2.61%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 14.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY • 56.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+3.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IDXG)Realized 20D OHLCV Swing Band: ±9.4%

Deterministic 5-Pillar Attribution (66/100 Composite)

🔍 WHY IDXG SCORES 66/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (23% of score)

FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 50 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality9/20 pts (-11 pt drag)

Capital intensity & 10.5% operating margin leave 11 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$6.00-14.2% Next Q

Q2 (-2Q)

Grade B$5.15+26.2% Next Q

Q3 (-1Q)

Grade B-$6.50-12% Next Q

Current

Grade C+$5.72+1.4% Hist 90D α

Trajectory: B+ (74) → C+ (66)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IDXG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 66/100 (C+) score, IDXG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.70) or 200D SMA ($2.74) invalidates the momentum regime and cuts Target Base ($5.93) toward Bear Floor ($4.63).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IDXG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IDXG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 66%NO 34%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How IDXG Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$5.5M (14.1% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $40.0M

FY24

Rev $46.9M

FY25

Rev $38.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$38.7M	62.3%	10.5%	$24.6M	$5.5M	16.2%
FY 2024	$46.9M	63.8%	17.3%	$6.7M	$3.8M	95%
FY 2023	$40.0M	62.3%	9.9%	$2.0M	$3.8M	16.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IDXG)

✓Walkthrough of IDXG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IDXG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +188.89%▼ DESCENDING CHANNEL

2026-10-30O $5.59H $5.72L $5.59C $5.72VOL 500

RES: $6.33SUP: $0.86SMA50: $5.70SMA200: $2.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IDXG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IDXG Butterfly Map → + Track IDXG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-11.1%/yr Implied 5Y Growth

vs. -17.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IDXG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IDXG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IDXG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IDXG)

Industrials Rank #109 of 485 ⚔️ JBDI vs IDXG Full Matrix →

1. Head-to-Head Industrials Peer Comparison (IDXG vs. JBDI, BHST, RML, STKE)

Industry: Diversified Equities (43 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, Interpace Biosciences Inc. (IDXG) ranks #109 by composite RQD confidence (66/100, grade C+) and #430 by equity capitalization ($23.2M). Within this direct 5-issuer industry benchmark cohort, IDXG leads on earnings valuation at N/A trailing P/E, while IDXG leads on capital efficiency and profitability with 16.2% ROIC and 62.3% gross margin. IDXG currently leads its immediate peer cohort in composite quantitative strength at 66/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IDXG ACTIVE Interpace Biosciences Inc.	C+	66/100	—	62.3%	16.2%	+15.56%	$23.2M	Benchmark Subject
JBDI JBDI Holdings Limited	D	45/100	—	49.9%	—	+0.42%	$22.9M	/jbdi-vs-idxg →
BHST BioHarvest Sciences Inc.	E	34/100	—	59.3%	-35.0%	-5.68%	$37.6M	/bhst-vs-idxg →
RML Resolution Minerals Ltd	D+	58/100	—	—	—	-1.99%	$44.1M	/rml-vs-idxg →
STKE Sol Strategies Inc.	D	50/100	—	—	—	-1.16%	$50.5M	/stke-vs-idxg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001054102

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Interpace Biosciences Inc. (IDXG) reported GAAP revenue of $38.7M (-17.5% vs. FY2024 revenue of $46.9M , and -3.3% cumulative change since FY2023) , GAAP net income of $24.6M, operating cash flow of $5.8M, and free cash flow of $5.5M (+45.2% YoY). On the balance sheet, IDXG closed FY2025 with $33.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$38.7M	$24.6M	$5.8M	$5.5M	$33.8M	—
FY2024 (FY)	2024-12-31	$46.9M	$6.7M	$4.6M	$3.8M	$14.8M	—
FY2023 (FY)	2023-12-31	$40.0M	$2.0M	$3.8M	$3.8M	—	—

3. IDXG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IDXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Interpace Biosciences Inc. (NASDAQ: IDXG) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $5.72 (+15.56% 1D, market cap $23.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 485 tracked Industrials issuers, IDXG ranks #109 in composite RQD confidence.

How does IDXG compare to JBDI and BHST in the Industrials sector?

Within the Industrials sector (Diversified Equities), IDXG carries a Roarable C+ (66/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of 16.2%. By comparison, JBDI (JBDI Holdings Limited) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $22.9M) and BHST (BioHarvest Sciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, IDXG leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IDXG?

Per IDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001054102), Interpace Biosciences Inc. generated $38.7M in revenue (-17.5% YoY), $24.6M in net income, and $5.5M in free cash flow against $33.8M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IDXG trading relative to its 50-day, 200-day, and 52-week technical levels?

IDXG last traded at $5.72 (+15.56% on volume of 5,107 shares), positioning the stock +0.35% above its 50-day simple moving average ($5.70) and +108.76% above its 200-day simple moving average ($2.74). Across its 52-week range of $0.81 to $7.80, IDXG sits at the 70.2% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($5.18 to $6.26).

IDXG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Interpace Biosciences Inc. (IDXG)?

In FY 2025 (10-K), IDXG converted $38.7M of revenue into a 62.3% gross margin, 10.5% operating margin, and $5.5M in free cash flow (14.1% FCF margin).

Direct Sub-Reports: IDXG RQD Cockpit IDXG 12M Forecast IDXG Earnings & Move IDXG Dividends & DRIP IDXG Insiders & 13F IDXG Whale Options IDXG Profit Sankey IDXG News & Why